JP2023524692A5 - - Google Patents

Info

Publication number
JP2023524692A5
JP2023524692A5 JP2022566135A JP2022566135A JP2023524692A5 JP 2023524692 A5 JP2023524692 A5 JP 2023524692A5 JP 2022566135 A JP2022566135 A JP 2022566135A JP 2022566135 A JP2022566135 A JP 2022566135A JP 2023524692 A5 JP2023524692 A5 JP 2023524692A5
Authority
JP
Japan
Prior art keywords
compound
process according
solvent
reaction mixture
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022566135A
Other languages
English (en)
Japanese (ja)
Other versions
JP7728795B2 (ja
JP2023524692A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/030035 external-priority patent/WO2021222673A1/en
Publication of JP2023524692A publication Critical patent/JP2023524692A/ja
Publication of JP2023524692A5 publication Critical patent/JP2023524692A5/ja
Priority to JP2025104881A priority Critical patent/JP2025128388A/ja
Application granted granted Critical
Publication of JP7728795B2 publication Critical patent/JP7728795B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022566135A 2020-04-30 2021-04-30 キナーゼ阻害剤を調製するためのプロセス Active JP7728795B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025104881A JP2025128388A (ja) 2020-04-30 2025-06-20 キナーゼ阻害剤を調製するためのプロセス

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063017739P 2020-04-30 2020-04-30
US63/017,739 2020-04-30
PCT/US2021/030035 WO2021222673A1 (en) 2020-04-30 2021-04-30 Processes for the preparation of a kinase inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025104881A Division JP2025128388A (ja) 2020-04-30 2025-06-20 キナーゼ阻害剤を調製するためのプロセス

Publications (3)

Publication Number Publication Date
JP2023524692A JP2023524692A (ja) 2023-06-13
JP2023524692A5 true JP2023524692A5 (cg-RX-API-DMAC7.html) 2024-04-30
JP7728795B2 JP7728795B2 (ja) 2025-08-25

Family

ID=76076455

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022566135A Active JP7728795B2 (ja) 2020-04-30 2021-04-30 キナーゼ阻害剤を調製するためのプロセス
JP2025104881A Pending JP2025128388A (ja) 2020-04-30 2025-06-20 キナーゼ阻害剤を調製するためのプロセス

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025104881A Pending JP2025128388A (ja) 2020-04-30 2025-06-20 キナーゼ阻害剤を調製するためのプロセス

Country Status (27)

Country Link
US (1) US12497367B2 (cg-RX-API-DMAC7.html)
EP (1) EP4143169B1 (cg-RX-API-DMAC7.html)
JP (2) JP7728795B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230005190A (cg-RX-API-DMAC7.html)
CN (2) CN115461328B (cg-RX-API-DMAC7.html)
AU (1) AU2021263474A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022021712A2 (cg-RX-API-DMAC7.html)
CA (1) CA3176042A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022003008A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022015205A2 (cg-RX-API-DMAC7.html)
CR (1) CR20220551A (cg-RX-API-DMAC7.html)
DK (1) DK4143169T3 (cg-RX-API-DMAC7.html)
FI (1) FI4143169T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20267875B (cg-RX-API-DMAC7.html)
HR (1) HRP20260608T1 (cg-RX-API-DMAC7.html)
IL (2) IL297684B2 (cg-RX-API-DMAC7.html)
LT (1) LT4143169T (cg-RX-API-DMAC7.html)
MA (1) MA59466B1 (cg-RX-API-DMAC7.html)
MX (1) MX2022013528A (cg-RX-API-DMAC7.html)
PE (1) PE20230110A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022552821A1 (cg-RX-API-DMAC7.html)
PT (1) PT4143169T (cg-RX-API-DMAC7.html)
RS (1) RS68116B1 (cg-RX-API-DMAC7.html)
SI (1) SI4143169T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202600219T1 (cg-RX-API-DMAC7.html)
TW (1) TWI887405B (cg-RX-API-DMAC7.html)
WO (1) WO2021222673A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20251184T1 (hr) * 2018-01-26 2025-12-05 Exelixis, Inc. Spojevi za liječenje poremećaja ovisnih o kinazi
AR127561A1 (es) * 2021-11-03 2024-02-07 Exelixis Inc Compuestos para el tratamiento de trastornos dependientes de cinasas

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1154105A (zh) 1994-06-08 1997-07-09 H·隆德贝克有限公司 4-芳基-1-(二氢化茚甲基、二氢苯并呋喃甲基或二氢苯并噻吩甲基)哌啶、-四氢吡啶或哌嗪类化合物
ZA954689B (en) 1994-06-08 1996-01-29 Lundbeck & Co As H 4-Aryl-1-(indanmethyl dihydrobenzofuranmethyl or dihydrobenzothiophenemethyl) piperidines tetrahydropyridines or piperazines
SMP200900002B (it) 2006-06-12 2010-01-19 Novartis Ag Sali di n-idrossi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]ammino]metil]fenil]-2e-2-propenammide
CN101466672B (zh) 2006-06-12 2012-05-16 诺瓦提斯公司 N-羟基-3-[4-[[[2-(2-甲基-1h-吲哚-3-基)乙基]氨基]甲基]苯基]-2e-2-丙烯酰胺的盐
CA2743416A1 (en) * 2008-11-13 2010-05-20 Exelixis Inc. Methods of preparing quinoline derivatives
TW201920110A (zh) * 2009-01-16 2019-06-01 美商艾克塞里克斯公司 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途
WO2012009722A1 (en) * 2010-07-16 2012-01-19 Exelixis, Inc. C-met modulator pharmaceutical compositions
PL2768796T3 (pl) 2011-10-20 2020-05-18 Exelixis, Inc. Sposób wytwarzania pochodnych chinoliny
EA033834B1 (ru) 2014-07-31 2019-11-29 Exelixis Inc Способ получения кабозантиниба, меченного фтором-18, и его аналогов
AU2019212800B2 (en) 2018-01-26 2024-05-23 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
SG11202006945PA (en) 2018-01-26 2020-08-28 Exelixis Inc Compounds for the treatment of kinase-dependent disorders
HRP20251184T1 (hr) * 2018-01-26 2025-12-05 Exelixis, Inc. Spojevi za liječenje poremećaja ovisnih o kinazi
PL3894012T4 (pl) * 2018-12-13 2026-01-05 Exelixis, Inc. Postacie krystaliczne i postacie soli inhibitora kinazy
CN109761899B (zh) * 2019-02-14 2022-11-15 广州六顺生物科技股份有限公司 喹啉衍生物、其药学上可接受的盐或其溶剂合物、其应用、药物及药物组合物

Similar Documents

Publication Publication Date Title
JP6307087B2 (ja) ベンズアミド化合物の合成に有用な化合物
JP6811717B2 (ja) トピロキソスタット及びその中間体の調製のための方法
TWI697494B (zh) 科帕利普(copanlisib)及其二鹽酸鹽之合成
KR20180038460A (ko) 세포독성 벤조다이아제핀 유도체의 제조 방법
JP4390861B2 (ja) アクリジン誘導体多剤耐性阻害薬の合成
JP2004517897A (ja) テモゾロミドおよびアナログの合成
JP6014912B2 (ja) ベンダムスチンアルキルエステル、ベンダムスチン、およびそれらの誘導体の製造のためのプロセス
JP2007522213A (ja) 置換されたトリアゾール化合物の製造方法
RU2194706C2 (ru) Способ получения дигидрохлорида 1-[[[5-(4-хлорфенил)-2-фуранил]метилен]амино]-3-[4-(4-метил-1-пиперазинил) бутил]-2,4-имидазолидиндиона
KR100574350B1 (ko) 2-아미노피리딘 유도체의 제조방법
JP2024509995A (ja) リスジプラムを調製するための方法
JP2023548368A5 (cg-RX-API-DMAC7.html)
JP4157766B2 (ja) 置換イミダゾピリジン化合物の製造方法
JP5453026B2 (ja) ヒドラジノトリアジン誘導体の製造方法、5−アミノピラゾール誘導体の製造方法、及び、5−アミノピラゾール誘導体
RU2194705C2 (ru) Способ получения 1,3-дизамещенных 4-оксоциклических мочевин
CN105294697B (zh) 2-氨基-5,8-二甲氧基[1,2,4]三唑并[1,5-c]嘧啶的合成方法
JP7683005B2 (ja) Pi3k阻害剤としての化合物の製造方法及びその製造のための中間体化合物
JP2026058357A (ja) イミダゾピリジノン化合物の製造方法及び中間体
JPWO2005063678A1 (ja) フェニル酢酸誘導体の製造方法
CN118834203A (zh) 瑞卢戈利中间体的制备方法
KR101152607B1 (ko) 6-[4-(2-피페리딘-1-일-에톡시)-페닐]-3-피리딘-4-일-피라졸로[1,5-a]피리미딘의 제조방법
SK50402005A3 (sk) Spôsob prípravy zaleplonu
CN119954778A (zh) 一种来那卡帕韦钠及其系列中间体化合物的合成方法
CN116804009A (zh) 用于合成TGF-β抑制剂的中间体及使用该中间体制备TGF-β抑制剂的方法
JPS6145622B2 (cg-RX-API-DMAC7.html)